Board of Directors
Per has more than 35 years of international experience in the diagnostic industry. His recent positions have covered executive management positions as CTO in Phadia and as CTO in Thermo Fischer Scientific ImmunoDiagnostics division. He holds a PhD in cell biology, MBA studies in Management of Innovation, and is appointed assistant professor at the Uppsala University and at the Veterinary Faculty, Swedish Agricultural University. Per is currently working as a senior advisor and board member for several companies and industry organizations and he is actively involved as a co-founder and chairperson in several diagnostic companies. Per also serves as scientific advisor to the UK listed Intuitive Investments Group plc, a venture fund concentrating on investing in fast-growing and/or high potential life sciences businesses.
Camilla Huse Bondesson
Camilla holds an Executive MBA from Stockholm University and is currently Chairman of the Board of Immuneed AB and TdB Labs AB. Camilla has over 30 years of international operational and strategic experience from leading positions in companies in the biotechnology field, including as head of Behring Diagnostica AB, international product manager for Biacore, marketing manager for Amersham Biosciences (now Cytiva) and VP Marketing for Gyros AB.
Since 2004, Camilla has worked as a consultant and partner at Conlega, a consulting company focusing on Life Science.
Staffan holds a PhD from KTH Royal Institute of Technology in Stockholm and has over 23 years of experience in the pharmaceutical industry. He is currently CEO of Infant Bacterial Therapeutics AB.
Besides his role as Head of Medical Devices at the Swedish Medical Products Agency, he has also been Vice President of Nicox France, and had management positions at AstraZeneca.
Staffan has particularly experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan.
Andrew holds a PhD in Biochemistry from the University of Manchester in England, and a MBA in Strategic Management from John F. Kennedy University in the US. He has more than 30 years of international experience from executive management positions and senior roles in the life science and diagnostic industries. Andrew currently holds the position as Vice President in the Corporate Business Development team in Bio-Rad Laboratories Inc, where he is focused on identifying M&A targets and managing the Corporate Venture fund, which introduced him to GA originally.
Rune holds a Master of Science in Business and Economics (siviløkonom) from Copenhagen School of Economics and Business Administration. He is a Norwegian citizen with residence in Oslo, Norway. Rune is currently a Partner in Televenture Management.
Before joining Televenture, Rune was a private investor and a senior adviser for European companies working in both Asia and the Middle East.
Rune has held several board positions in Norwegian investment companies.